Drug ID:Drug115
Drug Name:Apixaban
CID:10182969
DrugBank ID:DB06605
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT03935451
Molecular Formula:C25H25N5O4
Molecular Weight:459.5 g/mol
Isomeric SMILES:COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
Synonyms:Apixaban; 503612-47-3; BMS-562247-01; BMS 562247-01; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; apixabanum; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; UNII-3Z9Y7UWC1J; 3Z9Y7UWC1J; CHEBI:72296
Phase 0: 5
Phase 1: 52
Phase 2: 52
Phase 3: 64
Phase 4: 57
Description:Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor (of both free and prothrombinase-bound FXa independently of antithrombin III) for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. FDA approved on December 28, 2012.

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt960 10182969 Apixaban 2159 F10 Homo sapiens (human) None
dt961 10182969 Apixaban 2359 FPR3 Homo sapiens (human) Inhibitor
dt962 10182969 Apixaban 1577 CYP3A5 Homo sapiens (human) None
dt963 10182969 Apixaban 1066 CES1 Homo sapiens (human) None
dt964 10182969 Apixaban 2159 F10 Homo sapiens (human) 17914785 None
dt965 10182969 Apixaban 2147 F2 Homo sapiens (human) 17914785 None
dt966 10182969 Apixaban 338 APOB Homo sapiens (human) None
dt967 10182969 Apixaban 5447 POR Homo sapiens (human) None
dt968 10182969 Apixaban 2159 F10 Homo sapiens (human) Coagulation factor X inhibitor

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03935451 Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease EARLY_PHASE1 UNKNOWN McMaster University IBD|Venous Thromboembolism|Crohn Disease|Ulcerati… DRUG: Apixaban 2.5 milligram|DRUG: Placebo Oral T… Details
NCT05707429 Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease(Inactive Stage) NULL COMPLETED Assiut University Sexual Function Disturbances|Inflammatory Bowel D… OTHER: The Arabic version of The International In… Details
NCT05701501 Clinical Study of Vitamin B5 in Adjuvant Treatment of IBD NA UNKNOWN Changhai Hospital Inflammatory Bowel Diseases DRUG: Vitamin B5 Tablets|DRUG: placebo Details
NCT05688852 VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease PHASE2 TERMINATED Ventyx Biosciences, Inc Crohn Disease DRUG: VTX958|DRUG: VTX958|DRUG: VTX958 Placebo Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05684484 Role of Roflumilast in Ulcerative Colitis PHASE4 COMPLETED Tanta University Ulcerative Colitis DRUG: Roflumilast 500 MCG Oral Tablet [DALIRESP]|… Details
NCT05668013 A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease PHASE2 ACTIVE_NOT_RECRUITING Teva Branded Pharmaceutical Products R&D LLC Crohn Disease|Colitis, Ulcerative DRUG: TEV-48574 Dose Regimen A|DRUG: TEV-48574 Do… Details
NCT05666960 R-3750 in Patients With Mild to Moderate Ulcerative Colitis PHASE1 RECRUITING Rise Therapeutics LLC Ulcerative Colitis Chronic Mild|Ulcerative Coliti… DRUG: R-3750 Details
NCT05663671 Evaluate Established Anti-DEFA5 mAbs Diagnostic Efficacy and Safety in IBD NULL UNKNOWN Meharry Medical College Inflammatory Bowel Diseases|Ulcerative Colitis|Cr… DIAGNOSTIC_TEST: Diagnostic Test Details
NCT05659953 LMT503 First-in-human SAD, MAD, and FE Study PHASE1 NOT_YET_RECRUITING Lmito Therapeutics Inc. Inflammatory Bowel Disease|Colitis, Ulcerative|Cr… DRUG: LMT503|DRUG: Placebo Details
NCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years PHASE3 RECRUITING Ardelyx Irritable Bowel Syndrome With Constipation (IBS-C) DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… Details
NCT05638347 A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect. PHASE1 COMPLETED Atridia Pty Ltd. Inflammatory Bowel Disease DRUG: HRS-7085 tablets|DRUG: Placebo tablet Details
NCT05624801 Cholecalciferol Comedication in Patients With Chronic Inflammatory Bowel Diseases (Crohn's Disease or Ulcerative Colitis) - the 5C-study PHASE3 Recruiting University Hospital, Basel, Switzerland IBD Drug: D3 VitaCaps Details
NCT07168434 Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome PHASE3 RECRUITING Biocodex IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… Details
NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC PHASE2 ACTIVE_NOT_RECRUITING Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Inflammatory Bowel Diseases|Colitis, Ulcerative DRUG: MORF-057|DRUG: Placebo Details
NCT05549323 A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis PHASE1 TERMINATED Pfizer Ulcerative Colitis DRUG: PF-07054894|DRUG: Placebo Details
NCT07161297 Remimazolam for Colonoscopy in IBD Patients PHASE4 NOT_YET_RECRUITING Humanitas Clinical and Research Center IBD (Inflammatory Bowel Disease) DRUG: Intravenous remimazolam (5 mg initially, wi… Details
NCT05499130 A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease PHASE2 COMPLETED Teva Branded Pharmaceutical Products R&D, Inc. Crohn Disease|Colitis, Ulcerative DRUG: TEV-48574|DRUG: Placebo Details
NCT05486104 Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Ganzhou Hemay Pharmaceutical Co., Ltd Moderate to Severe Ulcerative Colitis DRUG: Hemay005 tablets|DRUG: Hemay005 placebo tab… Details
NCT07156929 Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation NA COMPLETED University Hospital Schleswig-Holstein Respiratory Infection (for Example, Pneumonia, Br… DIETARY_SUPPLEMENT: Controlled-ileocolonic-releas… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S01 Anti-inflammatory inflammatory 5-Aminosalicylates (5-ASAs); corticosteroids Crohn's disease and ulcerative colitis are the two main com… Details
S02 Immunosuppression Classic immunosuppressive drugs azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus Ciclosporin-A and tacrolimus bind to specific intracellular… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

Apixaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis in Colorectal…

PMID: 40505290
Year: 2025
Relationship Type: Association Score: 6.5

INTRODUCTION: Guidelines recommend postoperative venous thromboembolism (VTE) prophylaxis in colorectal cancer patients, as well as others at high ri…

View Details
[Monotherapy using a direct oral anticoagulant (apixaban) for catheter thrombos…

PMID: 33177262
Year: 2020
Relationship Type: Treatment Score: 6.5

A 20-year-old woman with ulcerative colitis flare was admitted to Fukui Red Cross Hospital. During treatment with granulocyte and monocyte apheresis …

View Details